Intellectual Product
Appeals Court Upholds FDA’s Denial of Fast Track Designation for Vanda’s Gastroparesis Drug
FDA, Vanda Pharmaceuticals, Fast Track Designation, Gastroparesis, Drug Approval Process
Samsung Biologics Embarks on New Phase of Growth with Bio Campus II and ADC Services
Samsung Biologics, Bio Campus II, Plant 5, antibody-drug conjugate (ADC) services, capacity expansion, digital transformation, contract development and manufacturing organization (CDMO)
BridgeBio Pharma Reports Strong Commercial Progress and Pipeline Updates for 2025
BridgeBio Pharma, Attruby, commercial progress, pipeline updates, 2025 milestones, rare genetic diseases, Phase 3 clinical trials, FORTIFY, CALIBRATE, PROPEL 3.
Ouro Medicines Launches with $120M Funding to Develop Immune Reset Therapeutics for Chronic Immune-Mediated Diseases
Ouro Medicines, Immune Reset Therapeutics, Chronic Immune-Mediated Diseases, T Cell Engagers, B Cell Mediated Diseases, GSK, Monograph Capital, TPG Life Sciences Innovations, NEA, Norwest Venture Partners
Moderna CEO Reflects on 2024 Challenges and Advances in Shareholder Letter
Moderna, shareholder letter, 2024 review, RSV vaccine, COVID-19 vaccine, mRNA medicines, Stéphane Bancel
Citius Oncology Explores Strategic Alternatives Ahead of LYMPHIR Commercial Launch
Citius Oncology, LYMPHIR, strategic alternatives, commercial launch, cutaneous T-cell lymphoma, immunotherapy
Abbott and Dexcom Reach 10-Year Settlement Over Diabetes Sensor Patent Disputes
Abbott, Dexcom, diabetes sensor, patent litigation, settlement, 10-year truce, continuous glucose monitoring (CGM)
Pfizer Terminates Hemophilia A Gene Therapy Partnership with Sangamo, Citing Commercial Viability Concerns
Pfizer, Sangamo Therapeutics, Hemophilia A, Gene Therapy, Commercial Viability, Partnership Termination
Biotech Industry Prepares for Trump 2.0: Regulatory Changes and M&A Activity Expected
Biotech industry, Trump 2.0, FDA changes, M&A activity, regulatory environment, pharmaceutical industry, healthcare policy
Corcept’s ALS Drug Trial Misses Primary Endpoint, Yet Shows Promising Survival Benefit
Corcept Therapeutics, Dazucorilant, ALS (Amyotrophic Lateral Sclerosis), Phase 2 trial, Survival benefit, Fast Track Designation, Cortisol modulator